Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 26

1.

Alcohol Increases Liver Progenitor Populations and Induces Disease Phenotypes in Human IPSC-Derived Mature Stage Hepatic Cells.

Tian L, Deshmukh A, Prasad N, Jang YY.

Int J Biol Sci. 2016 Jul 18;12(9):1052-62. doi: 10.7150/ijbs.15811. eCollection 2016.

2.

Expression kinetics of hepatic progenitor markers in cellular models of human liver development recapitulating hepatocyte and biliary cell fate commitment.

Chaudhari P, Tian L, Deshmukh A, Jang YY.

Exp Biol Med (Maywood). 2016 Sep;241(15):1653-62. doi: 10.1177/1535370216657901. Epub 2016 Jul 6.

3.

Current Management of Alcoholic Hepatitis and Future Therapies.

Saberi B, Dadabhai AS, Jang YY, Gurakar A, Mezey E.

J Clin Transl Hepatol. 2016 Jun 28;4(2):113-22. doi: 10.14218/JCTH.2016.00006. Epub 2016 Jun 15. Review.

4.

Gene correction in patient-specific iPSCs for therapy development and disease modeling.

Jang YY, Ye Z.

Hum Genet. 2016 Sep;135(9):1041-58. doi: 10.1007/s00439-016-1691-5. Epub 2016 Jun 2. Review.

PMID:
27256364
5.

Efficient and Controlled Generation of 2D and 3D Bile Duct Tissue from Human Pluripotent Stem Cell-Derived Spheroids.

Tian L, Deshmukh A, Ye Z, Jang YY.

Stem Cell Rev. 2016 Aug;12(4):500-8. doi: 10.1007/s12015-016-9657-5.

PMID:
27138846
6.

Genome editing systems in novel therapies.

Jang YY, Cai L, Ye Z.

Discov Med. 2016 Jan;21(113):57-64.

7.

IFNL3 genotype is associated with differential induction of IFNL3 in primary human hepatocytes.

Kurbanov F, Kim Y, Latanich R, Chaudhari P, El-Diwany R, Knabel M, Kandathil AJ, Cameron A, Cox A, Jang YY, Thomas DL, Balagopal A.

Antivir Ther. 2015;20(8):805-14. doi: 10.3851/IMP2974. Epub 2015 Jun 25.

8.

In Vitro Modeling of Alcohol-Induced Liver Injury Using Human-Induced Pluripotent Stem Cells.

Tian L, Prasad N, Jang YY.

Methods Mol Biol. 2016;1353:271-83. doi: 10.1007/7651_2014_168.

PMID:
25520290
9.

Efficient and allele-specific genome editing of disease loci in human iPSCs.

Smith C, Abalde-Atristain L, He C, Brodsky BR, Braunstein EM, Chaudhari P, Jang YY, Cheng L, Ye Z.

Mol Ther. 2015 Mar;23(3):570-7. doi: 10.1038/mt.2014.226. Epub 2014 Nov 24.

10.

Determination of Functional Activity of Human iPSC-Derived Hepatocytes by Measurement of CYP Metabolism.

Chaudhari P, Prasad N, Tian L, Jang YY.

Methods Mol Biol. 2016;1357:383-94. doi: 10.1007/7651_2014_145.

PMID:
25410290
11.

Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells.

Choi SM, Kim Y, Shim JS, Park JT, Wang RH, Leach SD, Liu JO, Deng C, Ye Z, Jang YY.

Hepatology. 2013 Jun;57(6):2458-68. doi: 10.1002/hep.26237.

12.

Roles of reactive oxygen species in the fate of stem cells.

Chaudhari P, Ye Z, Jang YY.

Antioxid Redox Signal. 2014 Apr 20;20(12):1881-90. doi: 10.1089/ars.2012.4963. Epub 2012 Nov 19. Review.

13.

Pluripotent stem cell-based cancer therapy: promise and challenges.

Sharkis SJ, Jones RJ, Civin C, Jang YY.

Sci Transl Med. 2012 Mar 28;4(127):127ps9. doi: 10.1126/scitranslmed.3003920. Review.

14.

Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells.

Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, Harris J, Yen RW, Ahuja N, Brock MV, Stearns V, Feller-Kopman D, Yarmus LB, Lin YC, Welm AL, Issa JP, Minn I, Matsui W, Jang YY, Sharkis SJ, Baylin SB, Zahnow CA.

Cancer Cell. 2012 Mar 20;21(3):430-46. doi: 10.1016/j.ccr.2011.12.029.

15.

Hematopoietic cells as sources for patient-specific iPSCs and disease modeling.

Ye Z, Liu CF, Jang YY.

Cell Cycle. 2011 Sep 1;10(17):2840-4. Epub 2011 Sep 1.

16.

Liver engraftment potential of hepatic cells derived from patient-specific induced pluripotent stem cells.

Choi SM, Kim Y, Liu H, Chaudhari P, Ye Z, Jang YY.

Cell Cycle. 2011 Aug 1;10(15):2423-7. Epub 2011 Aug 1.

17.

Reprogramming of EBV-immortalized B-lymphocyte cell lines into induced pluripotent stem cells.

Choi SM, Liu H, Chaudhari P, Kim Y, Cheng L, Feng J, Sharkis S, Ye Z, Jang YY.

Blood. 2011 Aug 18;118(7):1801-5. doi: 10.1182/blood-2011-03-340620. Epub 2011 May 31.

18.

In vivo liver regeneration potential of human induced pluripotent stem cells from diverse origins.

Liu H, Kim Y, Sharkis S, Marchionni L, Jang YY.

Sci Transl Med. 2011 May 11;3(82):82ra39. doi: 10.1126/scitranslmed.3002376.

20.

Generation of endoderm-derived human induced pluripotent stem cells from primary hepatocytes.

Liu H, Ye Z, Kim Y, Sharkis S, Jang YY.

Hepatology. 2010 May;51(5):1810-9. doi: 10.1002/hep.23626.

Supplemental Content

Loading ...
Support Center